Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
Research context
Hanmi Pharm. Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Hanmi Pharm. Co., Ltd is currently in a long term uptrend where the price is trading 3.0% above its 200 day moving average.
From a valuation standpoint, the stock is 59.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Hanmi Pharm. Co., Ltd's total revenue sank by 8.5% to $277B since the same quarter in the previous year.
Its net income has increased by 90.5% to $28B since the same quarter in the previous year.
Finally, its free cash flow grew by 4711.5% to $75B since the same quarter in the previous year.
Based on the above factors, Hanmi Pharm. Co., Ltd gets an overall score of 4/5.